January 2016

Codiak BioSciences closes $61M series B financing

Thursday, January 28, 2016

Codiak BioSciences Inc., a leading company in the field of exosome biology, announced the closing of its $61 million Series B round, bringing total investment in its combined Series A and B financing, announced in November 2015, to $92 million. Codiak intends to use the proceeds of this round primarily to advance research and clinical development of exosomes for therapeutic and diagnostic purposes. 

[Read More]

CRF Health appoints Claudine Paccio SVP

Tuesday, January 26, 2016

CRF Health, a global provider of eCOA solutions for the life sciences industry, announces the appointment of Claudine Paccio as the company’s senior vice president, Delivery Services. Paccio will head-up client delivery and development activities at CRF Health, where she will provide leadership, structure and processes to enhance the delivery of the company’s services and solutions to its rapidly growing customer base.

[Read More]

Virginia Bio expands board of directors

Tuesday, January 26, 2016

Virginia Bio, a statewide nonprofit association representing life science industry in the Commonwealth of Virginia, elected five new members to their board of directors for a term of three years. The election took place in December at the Virginia Bio Annual Membership in Richmond, Virginia.

[Read More]

Miami Cancer Institute names Mehta deputy director, radiology chief

Tuesday, January 26, 2016

Minesh Mehta, M.D., an expert in radiation oncology, proton therapy and cancer research, has joined the executive leadership of Miami Cancer Institute at Baptist Health South Florida as deputy director and chief of radiation oncology. Dr. Mehta will position Miami Cancer Institute’s proton therapy center—the only one of its kind in South Florida and one of fewer than two dozen of its kind in the U.S.—as the region’s top destination for this leading-edge treatment.

[Read More]

BioClinica acquires Clinverse

Monday, January 25, 2016

BioClinica, a specialty clinical trials services and technology provider, has acquired Clinverse. The acquisition expands Bioclinica’s offerings into the growing market of automated financial management technology solutions for global clinical trials. Clinverse is the latest investment that Bioclinica has completed to build the company into a leading provider of solutions that bring quality and efficiency to every phase of clinical trial development.  

[Read More]

Alkermes has positive phase III results for ALKS 5461 in major depressive disorder

Monday, January 25, 2016

Alkermes has announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase III efficacy studies to read out from the comprehensive FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression. Neither of the two studies met the prespecified primary efficacy endpoint, which compared ALKS 5461 to placebo on the change from baseline on the Montgomery–Åsberg Depression Rating Scale (MADRS).

[Read More]